KINERET 150 MG — DIN 02245913
ANAKINRA : 150 MG · SWEDISH ORPHAN BIOVITRUM AB (PUBL) · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is KINERET?
KINERET 150 MG contains ANAKINRA : 150 MG. It is listed in the Health Canada Drug Product Database under DIN 02245913, held by SWEDISH ORPHAN BIOVITRUM AB (PUBL), supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 22-Jun-2011. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is KINERET used for?
KINERET (anakinra) is indicated for: • reducing the signs and symptoms of active rheumatoid arthritis (RA) in patients 18 years of age or older. • inhibiting the progression of structural damage by reducing erosions and cartilage degradation in patients with active rheumatoid arthritis despite treatment with stable doses of methotrexate (MTX). KINERET can be used alone or in combination with other disease - modifying antirheumatic drugs (DMARDs), particularly MTX. KINERET (anakinra) is indicated for: • treatment of Neonatal - Onset Multisystem Inflammatory Disease (NOMID) in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Anakinra cost around the world?
Anakinra is listed on 10 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Czechia publishes a max producer price (ex-factory); Greece publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 1 | 2 | AUD███.██ |
| Norway | max AUP (pharmacy retail) | 1 | 2 | NOK███.██ |
| Romania | max producer price | 1 | 2 | RON███.██ |
| Czechia | max producer price (ex-factory) | 1 | 1 | CZK███.██ |
| Greece | producer price (ex-factory) | 1 | 1 | EUR███.██ |
| Iceland | max wholesale | 1 | 1 | ISK███.██ |
| Italy | ex-factory (classe H) | 1 | 1 | EUR███.██ |
| Luxembourg | reimbursement | 1 | 1 | EUR███.██ |
| Saudi Arabia | public | 1 | 1 | SAR███.██ |
| Slovakia | categorised final price | 1 | 1 | EUR███.██ |
13 pack listings across 10 brand entries and 10 price bases, refreshed 08 Sep 2026. Ranges span every Anakinra pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 150 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | SUBCUTANEOUS |
| Pack configuration (monograph) | dispensing pack of 7 syringes |
| Storage | null |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Anakinra |
|---|---|
| ATC code | L04AC03 |
| AHFS class | 24:24.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02245913 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2245913 |
| Brand name | KINERET |
| Generic / active ingredient | ANAKINRA : 150 MG |
| Market authorization holder | SWEDISH ORPHAN BIOVITRUM AB (PUBL) |
| Health Canada schedule | Prescription |
| ATC code | L04AC03 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L04AC |
| Current status | MARKETED |
| Status date | 22-Jun-2011 |
| Original market date | 2003-08-04 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
RA: 100 mg/day SC. NOMID: Starting dose 1-2 mg/kg/day SC, adjusted in 0.5-1.0 mg/kg increments. Maintenance 3-4 mg/kg/day (max 8 mg/kg/day). Administer at same time daily.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Known hypersensitivity to E. coli-derived proteins, KINERET, or any components of the product.
Warnings and precautions
Serious infections (discontinue if developed); Anaphylactic reactions; Neutropenia (monitor ANC); DRESS; Amyloidosis at injection sites; TB screening required before initiation.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
2 · Same class — other molecules in ATC L04AC
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Ustekinumab | FINLIUS · FINLIUS I.V. · JAMTEKI · JAMTEKI I.V. · +10 more | 25 | 24 | Yes |
| Tocilizumab | ACTEMRA · TYENNE | 10 | 10 | Yes |
| Mirikizumab | OMVOH | 7 | 7 | Yes |
| Rizankizumab | SKYRIZI | 7 | 5 | Yes |
| Secukinumab | COSENTYX | 6 | 5 | Yes |
| Guselkumab | TREMFYA · TREMFYA I.V. · TREMFYA ONE-PRESS | 5 | 4 | Yes |
| Bimekizumab | BIMZELX | 4 | 4 | Yes |
| Sarilumab | KEVZARA | 4 | 3 | Yes |
| Siltuximab | SYLVANT | 2 | 2 | Yes |
| Spesolimab | SPEVIGO | 2 | 2 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L04A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L04AX | Azathioprine · Dimethyl Fumarate · Lenalidomide · Methotrexate · Other Immunosuppressants · +3 more | 191 | 124 |
| L04AB | Adalimumab · Certolizumab Pegol · Etanercept · Golimumab · Infliximab | 71 | 55 |
| L04AA | Abatacept · Alefacept · Antilymphocyte Immunoglobulin (Horse) · Antithymocyte Immunoglobulin (Rabbit) · Apremilast · +4 more | 73 | 42 |
| L04AD | Ciclosporin · Tacrolimus | 49 | 30 |
| L04AK | Leflunomide · Teriflunomide | 44 | 25 |
| L04AH | Everolimus · Sirolimus | 36 | 23 |
| L04AF | Baricitinib · Deucravacitinib · Ritlecitinib · Tofacitinib · Upadacitinib | 23 | 19 |
| L04AG | Alemtuzumab · Anifrolumab · Belimumab · Efalizumab · Inebilizumab · +7 more | 20 | 15 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.